DK2902018T3 - Reduktion af intraokulært tryk med intracamerale bimatoprost-implantater - Google Patents
Reduktion af intraokulært tryk med intracamerale bimatoprost-implantater Download PDFInfo
- Publication number
- DK2902018T3 DK2902018T3 DK14194703.6T DK14194703T DK2902018T3 DK 2902018 T3 DK2902018 T3 DK 2902018T3 DK 14194703 T DK14194703 T DK 14194703T DK 2902018 T3 DK2902018 T3 DK 2902018T3
- Authority
- DK
- Denmark
- Prior art keywords
- implant
- prostaglandin
- eye
- use according
- implants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Prostaglandin til anvendelse i behandling af forhøjet intraokulært tryk (IOP) ved placering af et biologisk nedbrydeligt intraokulært implantat i et øje på en patient med behov for behandlingen; hvor: implantatet omfatter en prostaglandin i en mængde af 15-25 vægt-% af implantatets vægt, hvor prostaglandinen er forbundet med en biologisk nedbrydelig polymermatrix, derfrigiver en mængde af prostaglandinen, der er effektiv til at forebygge eller mindske et symptom på forhøjet IOP; og implantatet placeres i en intracameral lokalitet ved kl. 6-positionen for at udvide øjets afløbskanaler, der udgår fra Schlemms kanal, og for derved at blande prostaglandinen godt over hele det forreste segment via konvektionsstrømmene.
2. Prostaglandin til anvendelse ifølge krav 1, hvor implantatet placeres på en intracameral lokalitet ved kl. 6-positionen for at udvide karrene i det episclerale og conjunctivale veneplexus.
3. Prostaglandin til anvendelse ifølge krav 1, hvor implantatet placeres ved kl. 6-positionen i øjets forreste øjenkammer.
4. Prostaglandin til anvendelse ifølge krav 1, hvor implantatet placeres ved kl. 6-positionen i øjets iridocorneale vinkel.
5. Prostaglandin til anvendelse ifølge krav 1, hvor implantatet placeres i øjet ved anvendelse af en okulær implantatindføringsanordning omfattende: (a) en kanyle med en ydre væg, en proximal ende, en proximal endeåbning, en distal ende, en distal endeåbning og et lumen, der strækker sig gennem kanylen; (b) et okulært transplantat, der er dimensioneret og struktureret til implantation i et øje, hvilket okulære implantat placeres i lumenet; og (c) en kappe med en lukket distal ende, som er i kontakt med den ydre væg af kanylen og dækker kanylens distale ende og distale endeåbning, hvilken kappe er struktureret til at tillade, at kanylens distale ende og distale endeåbning passerer gennem kappen, når kanylen føres ind i et øje.
6. Prostaglandin til anvendelse ifølge krav 1, hvor prostaglandinen er en forbindelse med formlen (I):
hvor kortstregsbindingerne repræsenterer en enkelt- eller dobbeltbinding, der kan være i cis- eller trans-konfigurationen, A er et alkylen- eller alkenylenradikal med fra to til seks carbonatomer, hvilket radikal kan være afbrudt af ét eller flere oxidradikaler og substitueret med én eller flere hydroxy-, oxo-, alkyloxy- eller akylcarboxygrupper, hvor alkylradikalet omfatter fra ét til seks carbonatomer; B er et cycloalkylradikal med fra tre til syv carbonatomer, eller et arylradikal, der er udvalgt fra gruppen bestående af hydrocarbylaryl- og heteroarylradikaler med fra fire til ti carbonatomer, hvor heteroatomet er udvalgt fra gruppen bestående af nitrogen-, oxygen- og svovlatomer; X er -(OR4), hvor R4 er uafhængigt udvalgt fra gruppen bestående af hydrogen og et lavere alkylradikal med fra ét til seks carbonatomer; Z er =0; ét af Ri og R2 er =0, -OH eller en -0(C0)Re-gruppe, og det andet er -OH eller - 0(C0)R6, eller Ri er =0 og R2 er H; hvor R6 er en mættet eller umættet acyklisk carbonhydridgruppe med fra 1 til ca. 20 carbonatomer, eller -(CH2)mR7, hvor m er 0-10, og R7 er et cycloalkylradikal med fra tre til syv carbonatomer, eller hydrocarbylaryl eller heteroaryl, som defineret ovenfor.
7. Prostaglandin til anvendelse ifølge krav 6, hvor prostaglandinen har følgende formel (II):
hvor y er 0 eller 1, x er 0 eller 1 og x+y ikke begge er 1, Y er et radikal udvalgt fra gruppen bestående af alkyl, halo, nitro, amino, thiol, hydroxy, alkyloxy, alkylcarboxy og halo-substitueret alkyl, hvor alkylradikalet omfatter fra ét til seks carbonatomer, n er 0 eller et heltal på fra 1 til 3 og R3 er =0, —OH eller --0(C0)R.6 og kortstregslinjerne indikerer alfa-konfigurationen og fyldte trekanter indikerer beta-konfigurationen.
8. Prostaglandin til anvendelse ifølge krav 7, hvor prostaglandinen omfatter latanoprost, travoprost, salte deraf eller blandinger deraf.
9. Prostaglandin til anvendelse ifølge krav 8, hvor IOP'et reduceres med mindst 60 % i forhold til baseline.
10. Prostaglandin til anvendelse ifølge et hvilket som helst af de foregående krav, hvor diameteren af implantatet er mindre end 500 pm.
11. Prostaglandin til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor implantatet er dimensioneret til at passe til anatomien af øjets iridocorneale vinkel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/761,765 US8673341B2 (en) | 2004-04-30 | 2010-04-16 | Intraocular pressure reduction with intracameral bimatoprost implants |
| EP11717096.9A EP2558081B1 (en) | 2010-04-16 | 2011-04-14 | Intraocular pressure reduction with intracameral bimatoprost implants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2902018T3 true DK2902018T3 (da) | 2017-03-06 |
Family
ID=44194969
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11717096T DK2558081T3 (da) | 2010-04-16 | 2011-04-14 | Reduktion af intraokulært tryk med intrakamerale bimatoprost-implantater |
| DK16201104.3T DK3205333T3 (da) | 2010-04-16 | 2011-04-14 | Reduktion af intraokulært tryk med intracamerale prostamid-implantater |
| DK14194703.6T DK2902018T3 (da) | 2010-04-16 | 2011-04-14 | Reduktion af intraokulært tryk med intracamerale bimatoprost-implantater |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11717096T DK2558081T3 (da) | 2010-04-16 | 2011-04-14 | Reduktion af intraokulært tryk med intrakamerale bimatoprost-implantater |
| DK16201104.3T DK3205333T3 (da) | 2010-04-16 | 2011-04-14 | Reduktion af intraokulært tryk med intracamerale prostamid-implantater |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8673341B2 (da) |
| EP (5) | EP2902018B1 (da) |
| JP (5) | JP5982360B2 (da) |
| KR (2) | KR102252437B1 (da) |
| CN (2) | CN111450041A (da) |
| AU (1) | AU2011239642B2 (da) |
| BR (1) | BR112012026535A2 (da) |
| CA (2) | CA3010374A1 (da) |
| CY (3) | CY1115912T1 (da) |
| DK (3) | DK2558081T3 (da) |
| ES (3) | ES2528117T3 (da) |
| HU (2) | HUE040529T2 (da) |
| IL (1) | IL222457A (da) |
| MX (1) | MX2012012040A (da) |
| PL (3) | PL2558081T3 (da) |
| PT (3) | PT2902018T (da) |
| RU (1) | RU2586298C2 (da) |
| SG (2) | SG184905A1 (da) |
| SI (3) | SI2902018T1 (da) |
| TR (1) | TR201820663T4 (da) |
| WO (1) | WO2011130462A2 (da) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| AU2002258754B2 (en) | 2001-04-07 | 2006-08-17 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US9498457B2 (en) * | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| CA2668954C (en) | 2006-11-10 | 2020-09-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
| US8425449B2 (en) | 2009-07-09 | 2013-04-23 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
| WO2009111645A1 (en) | 2008-03-05 | 2009-09-11 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
| US9636255B2 (en) | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2012071476A2 (en) | 2010-11-24 | 2012-05-31 | David Haffner | Drug eluting ocular implant |
| CN104887388B (zh) | 2009-06-03 | 2018-01-09 | 弗赛特影像5股份有限公司 | 前段药物输送 |
| CN102481171B (zh) | 2009-07-09 | 2015-01-28 | 伊万提斯公司 | 用于输送眼部植入物的单人操作装置 |
| KR102126007B1 (ko) * | 2010-01-22 | 2020-06-24 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| US20130142858A1 (en) | 2010-05-17 | 2013-06-06 | Aerie Pharmaceuticals, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
| EP2701680B1 (en) | 2011-04-29 | 2018-10-31 | Allergan, Inc. | Sustained release latanoprost implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
| JP5989780B2 (ja) | 2011-09-14 | 2016-09-07 | フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． | 眼挿入装置および方法 |
| US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
| EP2830553B1 (en) | 2012-03-26 | 2017-12-27 | Glaukos Corporation | Apparatus for delivering multiple ocular implants |
| US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
| WO2014066653A1 (en) * | 2012-10-26 | 2014-05-01 | Allergan, Inc. | Ketorolac-containing sustained release intraocular drug delivery systems |
| US20150272877A1 (en) * | 2012-10-26 | 2015-10-01 | Allergan, Inc. | Ketorolac-containing sustained release drug delivery systems |
| WO2014066775A1 (en) | 2012-10-26 | 2014-05-01 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
| WO2014085450A1 (en) | 2012-11-28 | 2014-06-05 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
| CN105073153B (zh) * | 2013-03-15 | 2018-10-30 | 阿勒根公司 | 含有前列腺胺的眼内植入物 |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| JP2016515583A (ja) * | 2013-03-27 | 2016-05-30 | フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． | オキュラー・インサートおよびその使用方法 |
| RU2015146211A (ru) | 2013-04-01 | 2017-05-19 | Аллерган, Инк. | Микросферная система доставки лекарственного средства для замедленного внутриглазного высвобождения |
| SG10201800978UA (en) * | 2013-10-31 | 2018-03-28 | Allergan Inc | Prostamide-containing intraocular implants and methods of use thereof |
| EP3068371A1 (en) * | 2013-11-15 | 2016-09-21 | Glaukos Corporation | Ocular implants configured to store and release stable drug formulations |
| US20150342875A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2016011056A1 (en) | 2014-07-14 | 2016-01-21 | Ivantis, Inc. | Ocular implant delivery system and method |
| EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| WO2017015675A1 (en) * | 2015-07-23 | 2017-01-26 | Envisia Therapeutics, Inc. | Glaucoma treatment via intracameral ocular implants |
| US11197779B2 (en) | 2015-08-14 | 2021-12-14 | Ivantis, Inc. | Ocular implant with pressure sensor and delivery system |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| US11938058B2 (en) | 2015-12-15 | 2024-03-26 | Alcon Inc. | Ocular implant and delivery system |
| US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
| EP4197527A1 (en) | 2016-09-23 | 2023-06-21 | Incept, LLC | Intracameral drug delivery depots |
| USD841152S1 (en) | 2017-06-27 | 2019-02-19 | Monica S. Naylor | Eye drop container |
| US11376040B2 (en) | 2017-10-06 | 2022-07-05 | Glaukos Corporation | Systems and methods for delivering multiple ocular implants |
| USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
| EP3810082A1 (en) * | 2018-06-19 | 2021-04-28 | Cella Therapeutics, LLC | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
| MX2021015760A (es) | 2019-06-27 | 2022-04-06 | Layerbio Inc | Sistemas de administracion de medicamentos de dispositivos oculares. |
| CA3166738A1 (en) | 2020-02-06 | 2021-08-12 | Charles D. Blizzard | Travoprost compositions and methods for treating ocular diseases |
| JP2024503989A (ja) | 2021-01-11 | 2024-01-30 | アルコン インコーポレイティド | 粘弾性体送達のためのシステム及び方法 |
Family Cites Families (205)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT252264B (de) | 1965-03-17 | 1967-02-10 | Etapharm Chem Pharm Lab Ges M | Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates |
| US3393081A (en) * | 1966-12-06 | 1968-07-16 | Monsanto Co | Heat sealable moisture barrier coatings for polystyrene articles |
| US3749776A (en) | 1970-08-28 | 1973-07-31 | Allergan Pharma | Method for blocking prostaglandin activity |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| SE390255B (sv) | 1974-02-18 | 1976-12-13 | N G Y Torphammar | Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US3966749A (en) | 1975-02-10 | 1976-06-29 | Interx Research Corporation | Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof |
| US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US4144317A (en) | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
| US4052505A (en) | 1975-05-30 | 1977-10-04 | Alza Corporation | Ocular therapeutic system manufactured from copolymer |
| US4057619A (en) | 1975-06-30 | 1977-11-08 | Alza Corporation | Ocular therapeutic system with selected membranes for administering ophthalmic drug |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4186184A (en) | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
| US4190642A (en) | 1978-04-17 | 1980-02-26 | Alza Corporation | Ocular therapeutic system for dispensing a medication formulation |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4285957A (en) | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
| US4303637A (en) | 1980-04-04 | 1981-12-01 | Alza Corporation | Medication indicated for ocular hypertension |
| US4281654A (en) | 1980-04-07 | 1981-08-04 | Alza Corporation | Drug delivery system for controlled ocular therapy |
| US4396625A (en) | 1980-05-13 | 1983-08-02 | Sumitomo Chemical Company, Limited | Treatment of glaucoma or ocular hypertension and ophthalmic composition |
| US4425346A (en) | 1980-08-01 | 1984-01-10 | Smith And Nephew Associated Companies Limited | Pharmaceutical compositions |
| US4304765A (en) | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| JPS58126435U (ja) | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ｔｔｌオ−トストロボ用絞り制御回路 |
| US4454151A (en) | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| US4599353A (en) | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| DE3220156C2 (de) | 1982-05-28 | 1990-01-25 | Heida Houston Tex. Thurlow | Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel |
| US4649151A (en) | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US4478818A (en) | 1982-12-27 | 1984-10-23 | Alza Corporation | Ocular preparation housing steroid in two different therapeutic forms |
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| US4693885A (en) | 1984-07-18 | 1987-09-15 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| US4675338A (en) | 1984-07-18 | 1987-06-23 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| FR2577509B1 (fr) | 1985-02-21 | 1987-05-07 | Nirvana Espar Systems Sa | Mat de bateau a voile |
| US4656186A (en) | 1985-04-30 | 1987-04-07 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| FR2594438B1 (fr) | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| CA1311686C (en) | 1986-06-25 | 1992-12-22 | John Weldon Shell | Controlled release bioerodible drug delivery system |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5089509A (en) | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US4981871A (en) | 1987-05-15 | 1991-01-01 | Abelson Mark B | Treatment of ocular hypertension with class I calcium channel blocking agents |
| DE3734223A1 (de) | 1987-10-09 | 1989-04-20 | Boehringer Ingelheim Kg | Implantierbares, biologisch abbaubares wirkstofffreigabesystem |
| US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US4865846A (en) | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
| US5190966A (en) | 1988-07-06 | 1993-03-02 | Health Research, Inc. | Purified hematoporphyrin dimers and trimers useful in photodynamic therapy |
| US4968715A (en) | 1988-07-06 | 1990-11-06 | Health Research, Inc. | Use of purified hematoporphyrin trimers in photodynamic therapy |
| US5002962A (en) | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
| US5198460A (en) | 1988-07-20 | 1993-03-30 | Health Research Inc. | Pyropheophorbides and their use in photodynamic therapy |
| US5093349A (en) | 1988-07-20 | 1992-03-03 | Health Research Inc. | Photosensitizing agents |
| DE03014533T1 (de) | 1988-09-06 | 2004-07-15 | Pharmacia Ab | Prostaglandinderivative zur Behandlung von Glaukom oder okuläre Hypertension |
| US4935498A (en) | 1989-03-06 | 1990-06-19 | Board Of Regents, The University Of Texas System | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5171741A (en) | 1989-04-21 | 1992-12-15 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5173504A (en) | 1989-04-21 | 1992-12-22 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| US5034413A (en) | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US4932984A (en) | 1989-07-27 | 1990-06-12 | The Dow Chemical Company | Process for reduction of chlorinated solvent emissions |
| US5028624A (en) | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| US5268178A (en) | 1989-09-25 | 1993-12-07 | The Board Of Regents, The University Of Texas System | Biodegradable antibiotic implants and methods of their use in treating and preventing infections |
| US5503721A (en) | 1991-07-18 | 1996-04-02 | Hri Research, Inc. | Method for photoactivation |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5075115A (en) | 1990-04-02 | 1991-12-24 | Fmc Corporation | Process for polymerizing poly(lactic acid) |
| US5232844A (en) | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
| US5196460A (en) * | 1990-05-29 | 1993-03-23 | Repap Technologies Inc. | Rubber compositions containing high purity lignin derivatives |
| US5100431A (en) | 1990-09-27 | 1992-03-31 | Allergan, Inc. | Single stitch suture needle and method |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| CA2055522A1 (en) | 1990-12-12 | 1992-06-13 | Masako Andoh | Microspheres for ophthalmic use |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| WO1993000050A1 (en) | 1991-06-21 | 1993-01-07 | Genetics Institute, Inc. | Pharmaceutical formulations of osteogenic proteins |
| US5356629A (en) | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
| US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
| US5543154A (en) | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
| US5656297A (en) | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| US5384333A (en) | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
| IT1263116B (it) | 1992-04-09 | 1996-07-30 | Rotta Research Lab | Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico |
| US5655832A (en) | 1992-04-16 | 1997-08-12 | Tir Technologies, Inc. | Multiple wavelength light processor |
| US5244914A (en) | 1992-04-27 | 1993-09-14 | American Cyanamid Company | Stable porfimer sodium compositions and methods for their manufacture |
| US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US6217869B1 (en) | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
| US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| US5707643A (en) | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US6051576A (en) | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
| DE4403326C1 (de) | 1994-02-03 | 1995-06-22 | Hans Reinhard Prof Dr Koch | Intraokulare Linsenanordnung zur Astigmatismuskorrektur |
| US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5798349A (en) | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| US6270492B1 (en) | 1994-09-09 | 2001-08-07 | Cardiofocus, Inc. | Phototherapeutic apparatus with diffusive tip assembly |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| US5972326A (en) | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| CN1156961A (zh) | 1995-06-09 | 1997-08-13 | 欧罗赛铁克股份有限公司 | 产生长效局部麻醉的制剂和方法 |
| US5906920A (en) | 1995-08-29 | 1999-05-25 | The Salk Institute For Biological Studies | Methods for the detection of ligands for retinoid X receptors |
| US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| US5877207A (en) | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| AU4582797A (en) | 1996-09-13 | 1998-04-02 | Regents Of The University Of California, The | Methods for treatment of retinal diseases |
| US5913884A (en) | 1996-09-19 | 1999-06-22 | The General Hospital Corporation | Inhibition of fibrosis by photodynamic therapy |
| US6270749B1 (en) | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
| US6274614B1 (en) | 1997-02-11 | 2001-08-14 | Qlt Inc. | Methods, compositions and articles for reducing or preventing the effects of inflammation |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| AU727080B2 (en) | 1997-06-30 | 2000-11-30 | Allergan, Inc. | Calcium blockers to treat proliferative vitreoretinopathy |
| EP1003569B1 (en) | 1997-08-11 | 2004-10-20 | Allergan, Inc. | Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture |
| US6306426B1 (en) | 1997-08-11 | 2001-10-23 | Allergan Sales, Inc. | Implant device with a retinoid for improved biocompatibility |
| FR2767699A1 (fr) * | 1997-08-28 | 1999-02-26 | Oreal | Composition filmogene epaissie |
| US6207713B1 (en) * | 1997-09-17 | 2001-03-27 | Eric T. Fossel | Topical and oral delivery of arginine to cause beneficial effects |
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| US6271220B1 (en) | 1998-03-11 | 2001-08-07 | Allergan Sales, Inc. | Anti-angiogenic agents |
| AU4645099A (en) | 1998-07-09 | 2000-02-01 | Yoram Harth | Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea |
| CA2351734A1 (en) | 1998-11-20 | 2000-06-02 | University Of Connecticut | Generic integrated implantable potentiostat telemetry unit for electrochemical sensors |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6482854B1 (en) | 1999-03-25 | 2002-11-19 | Massachusetts Eye And Ear Infirmary | Glaucoma treatment |
| US6290713B1 (en) | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
| US6317616B1 (en) | 1999-09-15 | 2001-11-13 | Neil David Glossop | Method and system to facilitate image guided surgery |
| ATE414494T1 (de) | 1999-10-21 | 2008-12-15 | Alcon Inc | Medikamentenzuführeinrichtung |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US6728918B1 (en) | 1999-11-01 | 2004-04-27 | Matsushita Electric Industrial Co., Ltd. | Relay transmission method and system, and device used thereof |
| US6319273B1 (en) | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
| US6395787B1 (en) | 2000-02-08 | 2002-05-28 | Allergan Sales, Inc. | Ocular hypotensive lipids |
| CA2398901C (en) | 2000-02-10 | 2010-11-16 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
| US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
| US20040208910A1 (en) | 2000-04-26 | 2004-10-21 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of adrenergic agents |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| NZ521185A (en) | 2000-07-14 | 2005-02-25 | Allergan Inc | Compositions containing alpha-2-adrenergic agonist components |
| US6357568B1 (en) | 2000-09-27 | 2002-03-19 | Shou Mao Chen | Structure for protecting a luggage shell |
| WO2002058730A2 (en) | 2000-11-01 | 2002-08-01 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| ES2250504T3 (es) | 2000-11-29 | 2006-04-16 | Allergan Inc. | Prevencion del rechazo de injerto en el ojo. |
| US6595945B2 (en) | 2001-01-09 | 2003-07-22 | J. David Brown | Glaucoma treatment device and method |
| US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| WO2002089767A1 (en) | 2001-05-03 | 2002-11-14 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
| TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| US6713268B2 (en) | 2001-06-26 | 2004-03-30 | Allergan, Inc. | Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation |
| US20030220376A1 (en) | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
| US7749528B2 (en) | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| CA2461812C (en) | 2001-09-27 | 2011-09-20 | Allergan, Inc. | 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors |
| US20040058313A1 (en) | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| WO2003092665A2 (en) | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| TWI350170B (en) | 2002-08-29 | 2011-10-11 | Santen Pharmaceutical Co Ltd | Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
| TWI282271B (en) * | 2002-09-18 | 2007-06-11 | Allergan Inc | Apparatus for delivery of ocular implants |
| US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| ATE418323T1 (de) | 2002-11-06 | 2009-01-15 | Alza Corp | Depot-formulierungen mit verzögerter freisetzung |
| JP2004196787A (ja) | 2002-12-04 | 2004-07-15 | Santen Pharmaceut Co Ltd | 結膜下デポによるドラッグデリバリーシステム |
| US20040137059A1 (en) | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
| US20090148527A1 (en) | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US7186744B2 (en) | 2003-11-13 | 2007-03-06 | Allergan, Inc. | Prostamides for the treatment of glaucoma and related diseases |
| JP2007520496A (ja) | 2004-02-04 | 2007-07-26 | レットメッド ピーティーワイ リミテッド | 徐放性ステロイド組成物 |
| US20050244465A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Drug delivery systems and methods for treatment of an eye |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20050244478A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| US20050244466A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20050244462A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| US20050244471A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US20050244461A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US7091231B2 (en) | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
| RU2412933C2 (ru) | 2005-03-10 | 2011-02-27 | Аллерган, Инк. | Замещенные гамма-лактамы в качестве терапевтических агентов |
| US7427685B2 (en) | 2005-12-06 | 2008-09-23 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
| US7585895B2 (en) | 2005-12-06 | 2009-09-08 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
| KR20080082618A (ko) | 2005-12-16 | 2008-09-11 | 알콘, 인코퍼레이티드 | Ａｌｋ5 조절제를 사용한 안압의 조절 |
| EP1978892B1 (en) | 2006-01-17 | 2017-11-15 | Novartis Ag | Drug delivery treatment device |
| JP5528708B2 (ja) * | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | 安定な製剤ならびにそれらを調製および使用する方法 |
| US7592364B2 (en) | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US20080097335A1 (en) | 2006-08-04 | 2008-04-24 | Allergan, Inc. | Ocular implant delivery assemblies |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8846073B2 (en) * | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| US7589213B2 (en) | 2007-04-27 | 2009-09-15 | Old David W | Therapeutic substituted lactams |
| US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US7947732B2 (en) | 2007-07-13 | 2011-05-24 | Allergan, Inc. | Therapeutic substituted chlorocyclopentanols |
| US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
| IL186598A0 (en) | 2007-10-11 | 2008-11-03 | Mohammad Abdulrazik | Composition and method for the treatment or prevention of glaucoma and ocular hypertension |
| CA2705150C (en) | 2007-11-09 | 2016-06-14 | Allergan, Inc. | Substituted cyclopentanes having prostaglandin activity |
| EP2291368B1 (en) | 2008-04-24 | 2012-12-19 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| WO2009143288A1 (en) | 2008-05-20 | 2009-11-26 | Yale University | Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use |
| US20100098772A1 (en) | 2008-10-21 | 2010-04-22 | Allergan, Inc. | Drug delivery systems and methods for treating neovascularization |
| US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US9636255B2 (en) * | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| KR102126007B1 (ko) * | 2010-01-22 | 2020-06-24 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| US20130071349A1 (en) | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
-
2010
- 2010-04-16 US US12/761,765 patent/US8673341B2/en active Active
-
2011
- 2011-04-14 JP JP2013505123A patent/JP5982360B2/ja active Active
- 2011-04-14 SI SI201131120A patent/SI2902018T1/sl unknown
- 2011-04-14 SG SG2012077079A patent/SG184905A1/en unknown
- 2011-04-14 HU HUE16201104A patent/HUE040529T2/hu unknown
- 2011-04-14 KR KR1020187030085A patent/KR102252437B1/ko active IP Right Grant
- 2011-04-14 PL PL11717096T patent/PL2558081T3/pl unknown
- 2011-04-14 BR BR112012026535A patent/BR112012026535A2/pt not_active Application Discontinuation
- 2011-04-14 DK DK11717096T patent/DK2558081T3/da active
- 2011-04-14 CN CN202010034408.6A patent/CN111450041A/zh active Pending
- 2011-04-14 EP EP14194703.6A patent/EP2902018B1/en active Active
- 2011-04-14 TR TR2018/20663T patent/TR201820663T4/tr unknown
- 2011-04-14 DK DK16201104.3T patent/DK3205333T3/da active
- 2011-04-14 EP EP18187001.5A patent/EP3456323A1/en not_active Withdrawn
- 2011-04-14 PL PL14194703T patent/PL2902018T3/pl unknown
- 2011-04-14 KR KR1020127029910A patent/KR101915326B1/ko active IP Right Grant
- 2011-04-14 SG SG10201606415UA patent/SG10201606415UA/en unknown
- 2011-04-14 SI SI201130419T patent/SI2558081T1/sl unknown
- 2011-04-14 ES ES11717096.9T patent/ES2528117T3/es active Active
- 2011-04-14 PT PT141947036T patent/PT2902018T/pt unknown
- 2011-04-14 EP EP11717096.9A patent/EP2558081B1/en active Active
- 2011-04-14 PT PT117170969T patent/PT2558081E/pt unknown
- 2011-04-14 EP EP23202362.2A patent/EP4316594A3/en active Pending
- 2011-04-14 MX MX2012012040A patent/MX2012012040A/es active IP Right Grant
- 2011-04-14 SI SI201131645T patent/SI3205333T1/sl unknown
- 2011-04-14 ES ES16201104T patent/ES2707801T3/es active Active
- 2011-04-14 CN CN201180027636.XA patent/CN103002884B/zh active Active
- 2011-04-14 CA CA3010374A patent/CA3010374A1/en not_active Abandoned
- 2011-04-14 CA CA2796443A patent/CA2796443C/en active Active
- 2011-04-14 EP EP16201104.3A patent/EP3205333B1/en active Active
- 2011-04-14 ES ES14194703.6T patent/ES2617285T3/es active Active
- 2011-04-14 PT PT16201104T patent/PT3205333T/pt unknown
- 2011-04-14 WO PCT/US2011/032393 patent/WO2011130462A2/en active Application Filing
- 2011-04-14 DK DK14194703.6T patent/DK2902018T3/da active
- 2011-04-14 HU HUE14194703A patent/HUE033186T2/en unknown
- 2011-04-14 AU AU2011239642A patent/AU2011239642B2/en active Active
- 2011-04-14 RU RU2012147550/15A patent/RU2586298C2/ru active
- 2011-04-14 PL PL16201104T patent/PL3205333T3/pl unknown
-
2012
- 2012-10-15 IL IL222457A patent/IL222457A/en active IP Right Grant
-
2014
- 2014-03-07 US US14/201,194 patent/US20140316009A1/en not_active Abandoned
-
2015
- 2015-01-21 CY CY20151100056T patent/CY1115912T1/el unknown
-
2016
- 2016-06-03 JP JP2016111665A patent/JP6416154B2/ja active Active
-
2017
- 2017-02-24 CY CY20171100261T patent/CY1120299T1/el unknown
-
2018
- 2018-10-03 JP JP2018188114A patent/JP6683787B2/ja active Active
- 2018-12-27 CY CY181101399T patent/CY1121064T1/el unknown
-
2020
- 2020-03-26 JP JP2020055435A patent/JP6946503B2/ja active Active
-
2021
- 2021-09-15 JP JP2021150124A patent/JP2022000441A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2902018T3 (da) | Reduktion af intraokulært tryk med intracamerale bimatoprost-implantater | |
| AU2020201778B2 (en) | Prostamide-containing intraocular implants and methods of use thereof | |
| KR102126007B1 (ko) | 전방내 서방성 치료제 이식물 | |
| US20230026451A1 (en) | Intraocular pressure reduction with intracameral bimatoprost implants |